By
Trending Posts
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and…
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and what it signals…
Lilly’s U.S. Pricing Play: How Volume Economics Are…
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
With the Only FDA-Cleared Blood Test for Alzheimer’s…
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…
Can a $10 Billion Pipeline Opportunity Help Novartis…
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send an encouraging signal…
Approved Two Months Early, Can GSK’s Jideytro Become…
Key Highlights A Landmark Approval Reflecting the Strength of GSK’s Oncology Push GSK’s announcement that the FDA has…
Can Insilico Medicine’s 9-Month AI Drug Discovery Record…
Key Highlights A Landmark Shift in How Fast New Medicines Can Reach Patients Insilico Medicine’s disclosure that it…
Can Novo Nordisk’s Lawsuit Against Eli Lilly Push…
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to formally challenge Eli…
Roche’s Gazyva Wins Second FDA Priority Review in…
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement that the FDA…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader…
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Trending Posts
Latest Stories
Prosper Medical’s $16M Raise Is a Bet That AI Can Make Concierge Medicine Affordable — Not Just Convenient
Analysis of Prosper Medical’s seed round, its AI-powered care model, and what it signals about…
The FDA Just Created a Reimbursement Pathway for AI-Driven Care — Here’s Why That Matters More Than the Device, Dexcom the first participant in its TEMPO pilot.
Analysis of the FDA’s TEMPO pilot, its first AI-enabled participant, and what it signals for…
GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75%…
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for…
Gallery
